請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/21756
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈哲鯤 | |
dc.contributor.author | Shih-Ling Huang | en |
dc.contributor.author | 黃士玲 | zh_TW |
dc.date.accessioned | 2021-06-08T03:45:26Z | - |
dc.date.copyright | 2019-03-05 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-02-14 | |
dc.identifier.citation | 1 Shefner, J. M., Tyler, H. R. & Krarup, C. Abnormalities in the sensory action potential in patients with amyotrophic lateral sclerosis. Muscle Nerve 14, 1242-1246, doi:10.1002/mus.880141218 (1991).
2 Goetz, C. G. Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot. Muscle Nerve 23, 336-343 (2000). 3 Kumar, D. R., Aslinia, F., Yale, S. H. & Mazza, J. J. Jean-Martin Charcot: the father of neurology. Clin Med Res 9, 46-49, doi:10.3121/cmr.2009.883 (2011). 4 Hammer, R. P., Jr., Tomiyasu, U. & Scheibel, A. B. Degeneration of the human Betz cell due to amyotrophic lateral sclerosis. Exp Neurol 63, 336-346 (1979). 5 Bunina, T. L. [On intracellular inclusions in familial amyotrophic lateral sclerosis]. Zh Nevropatol Psikhiatr Im S S Korsakova 62, 1293-1299 (1962). 6 Leigh, P. N. et al. Ubiquitin deposits in anterior horn cells in motor neurone disease. Neurosci Lett 93, 197-203 (1988). 7 Leigh, P. N. et al. Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain 114 ( Pt 2), 775-788 (1991). 8 Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133, doi:10.1126/science.1134108 (2006). 9 Marin, B. et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol 46, 57-74, doi:10.1093/ije/dyw061 (2017). 10 Bruijn, L. I., Miller, T. M. & Cleveland, D. W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27, 723-749, doi:10.1146/annurev.neuro.27.070203.144244 (2004). 11 Rowland, L. P. & Shneider, N. A. Amyotrophic lateral sclerosis. N Engl J Med 344, 1688-1700, doi:10.1056/NEJM200105313442207 (2001). 12 Rothstein, J. D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Annals of neurology 65 Suppl 1, S3-9, doi:10.1002/ana.21543 (2009). 13 Pasinelli, P. & Brown, R. H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nature reviews. Neuroscience 7, 710-723, doi:10.1038/nrn1971 (2006). 14 Lomen-Hoerth, C., Anderson, T. & Miller, B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 59, 1077-1079 (2002). 15 Murphy, J., Henry, R. & Lomen-Hoerth, C. Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Archives of neurology 64, 330-334, doi:10.1001/archneur.64.3.330 (2007). 16 Hudson, A. J. Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review. Brain 104, 217-247 (1981). 17 Ling, S. C., Polymenidou, M. & Cleveland, D. W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79, 416-438, doi:10.1016/j.neuron.2013.07.033 (2013). 18 Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-1211, doi:10.1126/science.1165942 (2009). 19 Kwiatkowski, T. J., Jr. et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205-1208, doi:10.1126/science.1166066 (2009). 20 Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257-268, doi:10.1016/j.neuron.2011.09.010 (2011). 21 DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245-256, doi:10.1016/j.neuron.2011.09.011 (2011). 22 Pitt, D., Werner, P. & Raine, C. S. Glutamate excitotoxicity in a model of multiple sclerosis. Nature medicine 6, 67-70, doi:10.1038/71555 (2000). 23 Shaw, P. J. & Ince, P. G. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. Journal of neurology 244 Suppl 2, S3-14, doi:10.1007/BF03160574 (1997). 24 Van Den Bosch, L., Van Damme, P., Bogaert, E. & Robberecht, W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 1762, 1068-1082, doi:10.1016/j.bbadis.2006.05.002 (2006). 25 Niebroj-Dobosz, I. & Janik, P. Amino acids acting as transmitters in amyotrophic lateral sclerosis (ALS). Acta Neurol Scand 100, 6-11 (1999). 26 Turner, M. R., Goldacre, R., Ramagopalan, S., Talbot, K. & Goldacre, M. J. Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology 81, 1222-1225, doi:10.1212/WNL.0b013e3182a6cc13 (2013). 27 Kimura, F. et al. Amyotrophic lateral sclerosis patient antibodies label Ca2+ channel alpha 1 subunit. Annals of neurology 35, 164-171, doi:10.1002/ana.410350207 (1994). 28 Engelhardt, J. I., Siklos, L., Komuves, L., Smith, R. G. & Appel, S. H. Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons. Synapse 20, 185-199, doi:10.1002/syn.890200302 (1995). 29 Saleh, I. A. et al. Evaluation of humoral immune response in adaptive immunity in ALS patients during disease progression. Journal of neuroimmunology 215, 96-101, doi:10.1016/j.jneuroim.2009.07.011 (2009). 30 McCombe, P. A. & Henderson, R. D. The Role of immune and inflammatory mechanisms in ALS. Current molecular medicine 11, 246-254 (2011). 31 Baumann, J. Results of treatment of certain diseases of the central nervous system with ACTH and corticosteroids. Acta neurologica Scandinavica. Supplementum 13 Pt 2, 453-461 (1965). 32 Kelemen, J., Hedlund, W., Orlin, J. B., Berkman, E. M. & Munsat, T. L. Plasmapheresis with immunosuppression in amyotrophic lateral sclerosis. Archives of neurology 40, 752-753 (1983). 33 Brown, R. H., Jr., Hauser, S. L., Harrington, H. & Weiner, H. L. Failure of immunosuppression with a ten- to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis. Arch Neurol 43, 383-384 (1986). 34 Appel, S. H. et al. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol 45, 381-386 (1988). 35 Wright, E. M., Vogel, K. S. & Davies, A. M. Neurotrophic factors promote the maturation of developing sensory neurons before they become dependent on these factors for survival. Neuron 9, 139-150 (1992). 36 Yamada, M. K. et al. Brain-derived neurotrophic factor promotes the maturation of GABAergic mechanisms in cultured hippocampal neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience 22, 7580-7585 (2002). 37 Adler, R., Landa, K. B., Manthorpe, M. & Varon, S. Cholinergic neuronotrophic factors: intraocular distribution of trophic activity for ciliary neurons. Science 204, 1434-1436 (1979). 38 Yan, Q., Elliott, J. & Snider, W. D. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature 360, 753-755, doi:10.1038/360753a0 (1992). 39 Wong, V., Arriaga, R., Ip, N. Y. & Lindsay, R. M. The neurotrophins BDNF, NT-3 and NT-4/5, but not NGF, up-regulate the cholinergic phenotype of developing motor neurons. Eur J Neurosci 5, 466-474 (1993). 40 Funakoshi, H., Ohya, W., Kadoyama, K. & Nakamura, T. [ALS and neurotrophic factors--HGF as a novel neurotrophic and neuroregenerative factor]. Brain Nerve 59, 1195-1202 (2007). 41 Henriques, A., Pitzer, C. & Schneider, A. Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand? Front Neurosci 4, 32, doi:10.3389/fnins.2010.00032 (2010). 42 Ekestern, E. Neurotrophic factors and amyotrophic lateral sclerosis. Neurodegener Dis 1, 88-100, doi:10.1159/000080049 (2004). 43 Lowe, J. et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J Pathol 155, 9-15, doi:10.1002/path.1711550105 (1988). 44 Julien, J. P. & Kriz, J. Transgenic mouse models of amyotrophic lateral sclerosis. Biochim Biophys Acta 1762, 1013-1024, doi:10.1016/j.bbadis.2006.03.006 (2006). 45 Julien, J. P. A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis. Biochem Cell Biol 73, 593-597 (1995). 46 Trojsi, F., Monsurro, M. R. & Tedeschi, G. Exposure to environmental toxicants and pathogenesis of amyotrophic lateral sclerosis: state of the art and research perspectives. International journal of molecular sciences 14, 15286-15311, doi:10.3390/ijms140815286 (2013). 47 Zarei, S. et al. A comprehensive review of amyotrophic lateral sclerosis. Surgical neurology international 6, 171, doi:10.4103/2152-7806.169561 (2015). 48 Bozzoni, V. et al. Amyotrophic lateral sclerosis and environmental factors. Functional neurology 31, 7-19 (2016). 49 Alonso, A., Logroscino, G., Jick, S. S. & Hernan, M. A. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol 16, 745-751 (2009). 50 Mehta, P. et al. Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011. MMWR Suppl 63, 1-14 (2014). 51 McCombe, P. A. & Henderson, R. D. Effects of gender in amyotrophic lateral sclerosis. Gend Med 7, 557-570, doi:10.1016/j.genm.2010.11.010 (2010). 52 Renton, A. E., Chio, A. & Traynor, B. J. State of play in amyotrophic lateral sclerosis genetics. Nature neuroscience 17, 17-23, doi:10.1038/nn.3584 (2014). 53 Li, H. F. & Wu, Z. Y. Genotype-phenotype correlations of amyotrophic lateral sclerosis. Transl Neurodegener 5, 3, doi:10.1186/s40035-016-0050-8 (2016). 54 Chia, R., Chio, A. & Traynor, B. J. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 17, 94-102, doi:10.1016/S1474-4422(17)30401-5 (2018). 55 Turner, B. J. & Talbot, K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 85, 94-134, doi:10.1016/j.pneurobio.2008.01.001 (2008). 56 Gijselinck, I. et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 11, 54-65, doi:10.1016/S1474-4422(11)70261-7 (2012). 57 Boeve, B. F. et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 135, 765-783, doi:10.1093/brain/aws004 (2012). 58 Chio, A. et al. ALS/FTD phenotype in two Sardinian families carrying both C9ORF72 and TARDBP mutations. J Neurol Neurosurg Psychiatry 83, 730-733, doi:10.1136/jnnp-2012-302219 (2012). 59 Cooper-Knock, J. et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 135, 751-764, doi:10.1093/brain/awr365 (2012). 60 Hsiung, G. Y. et al. Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. Brain 135, 709-722, doi:10.1093/brain/awr354 (2012). 61 Mahoney, C. J. et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 135, 736-750, doi:10.1093/brain/awr361 (2012). 62 Simon-Sanchez, J. et al. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain 135, 723-735, doi:10.1093/brain/awr353 (2012). 63 Snowden, J. S. et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 135, 693-708, doi:10.1093/brain/awr355 (2012). 64 Lagier-Tourenne, C., Polymenidou, M. & Cleveland, D. W. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Human molecular genetics 19, R46-64, doi:10.1093/hmg/ddq137 (2010). 65 Lee, E. B., Lee, V. M. & Trojanowski, J. Q. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nature reviews. Neuroscience 13, 38-50, doi:10.1038/nrn3121 (2011). 66 Forman, M. S., Trojanowski, J. Q. & Lee, V. M. TDP-43: a novel neurodegenerative proteinopathy. Curr Opin Neurobiol 17, 548-555, doi:10.1016/j.conb.2007.08.005 (2007). 67 Buratti, E. Functional Significance of TDP-43 Mutations in Disease. Advances in genetics 91, 1-53, doi:10.1016/bs.adgen.2015.07.001 (2015). 68 Ou, S. H., Wu, F., Harrich, D., Garcia-Martinez, L. F. & Gaynor, R. B. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 69, 3584-3596 (1995). 69 Buratti, E. & Baralle, F. E. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 276, 36337-36343, doi:10.1074/jbc.M104236200 (2001). 70 Kuo, P. H., Doudeva, L. G., Wang, Y. T., Shen, C. K. & Yuan, H. S. Structural insights into TDP-43 in nucleic-acid binding and domain interactions. Nucleic Acids Res 37, 1799-1808, doi:10.1093/nar/gkp013 (2009). 71 Winton, M. J. et al. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem 283, 13302-13309, doi:10.1074/jbc.M800342200 (2008). 72 Ayala, Y. M. et al. Structural determinants of the cellular localization and shuttling of TDP-43. Journal of cell science 121, 3778-3785, doi:10.1242/jcs.038950 (2008). 73 Jiang, L. L. et al. The N-terminal dimerization is required for TDP-43 splicing activity. Sci Rep 7, 6196, doi:10.1038/s41598-017-06263-3 (2017). 74 Afroz, T. et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat Commun 8, 45, doi:10.1038/s41467-017-00062-0 (2017). 75 Wang, I. F., Wu, L. S., Chang, H. Y. & Shen, C. K. TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem 105, 797-806, doi:10.1111/j.1471-4159.2007.05190.x (2008). 76 Bhardwaj, A., Myers, M. P., Buratti, E. & Baralle, F. E. Characterizing TDP-43 interaction with its RNA targets. Nucleic Acids Res 41, 5062-5074, doi:10.1093/nar/gkt189 (2013). 77 Alami, N. H. et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 81, 536-543, doi:10.1016/j.neuron.2013.12.018 (2014). 78 Buratti, E. & Baralle, F. E. TDP-43: gumming up neurons through protein-protein and protein-RNA interactions. Trends Biochem Sci 37, 237-247, doi:10.1016/j.tibs.2012.03.003 (2012). 79 Freibaum, B. D., Chitta, R. K., High, A. A. & Taylor, J. P. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res 9, 1104-1120, doi:10.1021/pr901076y (2010). 80 Majumder, P., Chu, J. F., Chatterjee, B., Swamy, K. B. & Shen, C. J. Co-regulation of mRNA translation by TDP-43 and Fragile X Syndrome protein FMRP. Acta Neuropathol 132, 721-738, doi:10.1007/s00401-016-1603-8 (2016). 81 Bose, J. K., Huang, C. C. & Shen, C. K. Regulation of autophagy by neuropathological protein TDP-43. The Journal of biological chemistry 286, 44441-44448, doi:10.1074/jbc.M111.237115 (2011). 82 Chiang, P. M. et al. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc Natl Acad Sci U S A 107, 16320-16324, doi:10.1073/pnas.1002176107 (2010). 83 Wu, L. S. et al. TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis. Genesis 48, 56-62, doi:10.1002/dvg.20584 (2010). 84 Sephton, C. F. et al. TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem 285, 6826-6834, doi:10.1074/jbc.M109.061846 (2010). 85 Kraemer, B. C. et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol 119, 409-419, doi:10.1007/s00401-010-0659-0 (2010). 86 Wu, L. S., Cheng, W. C. & Shen, C. K. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. J Biol Chem 287, 27335-27344, doi:10.1074/jbc.M112.359000 (2012). 87 Liu, Y. C., Chiang, P. M. & Tsai, K. J. Disease animal models of TDP-43 proteinopathy and their pre-clinical applications. International journal of molecular sciences 14, 20079-20111, doi:10.3390/ijms141020079 (2013). 88 Tsao, W. et al. Rodent models of TDP-43: recent advances. Brain research 1462, 26-39, doi:10.1016/j.brainres.2012.04.031 (2012). 89 Arnold, E. S. et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proceedings of the National Academy of Sciences of the United States of America 110, E736-745, doi:10.1073/pnas.1222809110 (2013). 90 Polymenidou, M. et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nature neuroscience 14, 459-468, doi:10.1038/nn.2779 (2011). 91 Stribl, C. et al. Mitochondrial dysfunction and decrease in body weight of a transgenic knock-in mouse model for TDP-43. J Biol Chem 289, 10769-10784, doi:10.1074/jbc.M113.515940 (2014). 92 Capossela, S. et al. Growth defects and impaired cognitive-behavioral abilities in mice with knockout for Eif4h, a gene located in the mouse homolog of the Williams-Beuren syndrome critical region. Am J Pathol 180, 1121-1135, doi:10.1016/j.ajpath.2011.12.008 (2012). 93 Koyama, A. et al. Increased cytoplasmic TARDBP mRNA in affected spinal motor neurons in ALS caused by abnormal autoregulation of TDP-43. Nucleic Acids Res 44, 5820-5836, doi:10.1093/nar/gkw499 (2016). 94 Ayala, Y. M. et al. TDP-43 regulates its mRNA levels through a negative feedback loop. The EMBO journal 30, 277-288, doi:10.1038/emboj.2010.310 (2011). 95 Buratti, E. & Baralle, F. E. TDP-43: new aspects of autoregulation mechanisms in RNA binding proteins and their connection with human disease. FEBS J 278, 3530-3538, doi:10.1111/j.1742-4658.2011.08257.x (2011). 96 Avendano-Vazquez, S. E. et al. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev 26, 1679-1684, doi:10.1101/gad.194829.112 (2012). 97 Neumann, M. Molecular neuropathology of TDP-43 proteinopathies. International journal of molecular sciences 10, 232-246, doi:10.3390/ijms10010232 (2009). 98 Hasegawa, M. et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Annals of neurology 64, 60-70, doi:10.1002/ana.21425 (2008). 99 Xu, Y. F. et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience 30, 10851-10859, doi:10.1523/JNEUROSCI.1630-10.2010 (2010). 100 Igaz, L. M. et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. The Journal of clinical investigation 121, 726-738, doi:10.1172/JCI44867 (2011). 101 Wils, H. et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 107, 3858-3863, doi:10.1073/pnas.0912417107 (2010). 102 Wegorzewska, I., Bell, S., Cairns, N. J., Miller, T. M. & Baloh, R. H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 106, 18809-18814, doi:10.1073/pnas.0908767106 (2009). 103 Stallings, N. R., Puttaparthi, K., Luther, C. M., Burns, D. K. & Elliott, J. L. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol Dis 40, 404-414, doi:10.1016/j.nbd.2010.06.017 (2010). 104 Shan, X., Chiang, P. M., Price, D. L. & Wong, P. C. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc Natl Acad Sci U S A 107, 16325-16330, doi:10.1073/pnas.1003459107 (2010). 105 Giordana, M. T. et al. TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol 20, 351-360, doi:10.1111/j.1750-3639.2009.00284.x (2010). 106 Huang, C. C. et al. Metabolism and mis-metabolism of the neuropathological signature protein TDP-43. Journal of cell science 127, 3024-3038, doi:10.1242/jcs.136150 (2014). 107 Ling, S. C. et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proceedings of the National Academy of Sciences of the United States of America 107, 13318-13323, doi:10.1073/pnas.1008227107 (2010). 108 Pesiridis, G. S., Tripathy, K., Tanik, S., Trojanowski, J. Q. & Lee, V. M. A 'two-hit' hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion and impaired microtubule-dependent transport. J Biol Chem 286, 18845-18855, doi:10.1074/jbc.M111.231118 (2011). 109 Scotter, E. L., Chen, H. J. & Shaw, C. E. Erratum to: TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 12, 515-518, doi:10.1007/s13311-015-0351-0 (2015). 110 Neumann, M. et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. Journal of neuropathology and experimental neurology 66, 152-157, doi:10.1097/nen.0b013e31803020b9 (2007). 111 Zhang, C. & Saunders, A. J. An emerging role for Ubiquilin 1 in regulating protein quality control system and in disease pathogenesis. Discov Med 8, 18-22 (2009). 112 Che, M. X., Jiang, L. L., Li, H. Y., Jiang, Y. J. & Hu, H. Y. TDP-35 sequesters TDP-43 into cytoplasmic inclusions through binding with RNA. FEBS Lett 589, 1920-1928, doi:10.1016/j.febslet.2015.06.009 (2015). 113 Che, M. X., Jiang, Y. J., Xie, Y. Y., Jiang, L. L. & Hu, H. Y. Aggregation of the 35-kDa fragment of TDP-43 causes formation of cytoplasmic inclusions and alteration of RNA processing. FASEB J 25, 2344-2353, doi:10.1096/fj.10-174482 (2011). 114 Cannon, A. et al. Neuronal sensitivity to TDP-43 overexpression is dependent on timing of induction. Acta Neuropathol 123, 807-823, doi:10.1007/s00401-012-0979-3 (2012). 115 Xiao, S. et al. Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death. Acta Neuropathol 130, 49-61, doi:10.1007/s00401-015-1412-5 (2015). 116 Voigt, A. et al. TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PloS one 5, e12247, doi:10.1371/journal.pone.0012247 (2010). 117 Bilican, B. et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A 109, 5803-5808, doi:10.1073/pnas.1202922109 (2012). 118 Serio, A. et al. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc Natl Acad Sci U S A 110, 4697-4702, doi:10.1073/pnas.1300398110 (2013). 119 Kasai, T. et al. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol 117, 55-62, doi:10.1007/s00401-008-0456-1 (2009). 120 Scotter, E. L. et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. Journal of cell science 127, 1263-1278, doi:10.1242/jcs.140087 (2014). 121 Wang, I. F. et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci U S A 109, 15024-15029, doi:10.1073/pnas.1206362109 (2012). 122 Kleijnen, M. F. et al. The hPLIC proteins may provide a link between the ubiquitination machinery and the proteasome. Mol Cell 6, 409-419 (2000). 123 Buchberger, A. From UBA to UBX: new words in the ubiquitin vocabulary. Trends Cell Biol 12, 216-221 (2002). 124 Stieren, E. S. et al. Ubiquilin-1 is a molecular chaperone for the amyloid precursor protein. J Biol Chem 286, 35689-35698, doi:10.1074/jbc.M111.243147 (2011). 125 Lim, P. J. et al. Ubiquilin and p97/VCP bind erasin, forming a complex involved in ERAD. J Cell Biol 187, 201-217, doi:10.1083/jcb.200903024 (2009). 126 Kim, S. H. et al. Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1. J Biol Chem 284, 8083-8092, doi:10.1074/jbc.M808064200 (2009). 127 Budini, M., Buratti, E., Morselli, E. & Criollo, A. Autophagy and Its Impact on Neurodegenerative Diseases: New Roles for TDP-43 and C9orf72. Front Mol Neurosci 10, 170, doi:10.3389/fnmol.2017.00170 (2017). 128 Wang, H. Y., Wang, I. F., Bose, J. & Shen, C. K. Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics 83, 130-139 (2004). 129 Narayanan, R. K. et al. Identification of RNA bound to the TDP-43 ribonucleoprotein complex in the adult mouse brain. Amyotroph Lateral Scler Frontotemporal Degener 14, 252-260, doi:10.3109/21678421.2012.734520 (2013). 130 Coyne, A. N. et al. Futsch/MAP1B mRNA is a translational target of TDP-43 and is neuroprotective in a Drosophila model of amyotrophic lateral sclerosis. J Neurosci 34, 15962-15974, doi:10.1523/JNEUROSCI.2526-14.2014 (2014). 131 D'Alton, S. et al. Divergent phenotypes in mutant TDP-43 transgenic mice highlight potential confounds in TDP-43 transgenic modeling. PloS one 9, e86513, doi:10.1371/journal.pone.0086513 (2014). 132 Ditsworth, D. et al. Mutant TDP-43 within motor neurons drives disease onset but not progression in amyotrophic lateral sclerosis. Acta Neuropathol 133, 907-922, doi:10.1007/s00401-017-1698-6 (2017). 133 Tsai, K. J. et al. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. The Journal of experimental medicine 207, 1661-1673, doi:10.1084/jem.20092164 (2010). 134 McGoldrick, P., Joyce, P. I., Fisher, E. M. & Greensmith, L. Rodent models of amyotrophic lateral sclerosis. Biochim Biophys Acta 1832, 1421-1436, doi:10.1016/j.bbadis.2013.03.012 (2013). 135 White, M. A. et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nature neuroscience 21, 552-563, doi:10.1038/s41593-018-0113-5 (2018). 136 Fratta, P. et al. Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. The EMBO journal 37, doi:10.15252/embj.201798684 (2018). 137 Miller, R. G. et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73, 1218-1226, doi:10.1212/WNL.0b013e3181bc0141 (2009). 138 Gitcho, M. A. et al. TDP-43 A315T mutation in familial motor neuron disease. Annals of neurology 63, 535-538, doi:10.1002/ana.21344 (2008). 139 Kabashi, E. et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature genetics 40, 572-574, doi:10.1038/ng.132 (2008). 140 Walker, A. K. et al. ALS-associated TDP-43 induces endoplasmic reticulum stress, which drives cytoplasmic TDP-43 accumulation and stress granule formation. PloS one 8, e81170, doi:10.1371/journal.pone.0081170 (2013). 141 Wu, L. S., Cheng, W. C. & Shen, C. K. Similar dose-dependence of motor neuron cell death caused by wild type human TDP-43 and mutants with ALS-associated amino acid substitutions. Journal of biomedical science 20, 33, doi:10.1186/1423-0127-20-33 (2013). 142 Johnson, B. S. et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 284, 20329-20339, doi:10.1074/jbc.M109.010264 (2009). 143 Wichterle, H., Lieberam, I., Porter, J. A. & Jessell, T. M. Directed differentiation of embryonic stem cells into motor neurons. Cell 110, 385-397 (2002). 144 Chen, J. A. et al. Mir-17-3p controls spinal neural progenitor patterning by regulating Olig2/Irx3 cross-repressive loop. Neuron 69, 721-735, doi:10.1016/j.neuron.2011.01.014 (2011). 145 Mazzoni, E. O. et al. Saltatory remodeling of Hox chromatin in response to rostrocaudal patterning signals. Nature neuroscience 16, 1191-1198, doi:10.1038/nn.3490 (2013). 146 Guyenet, S. J. et al. A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. Journal of visualized experiments : JoVE, doi:10.3791/1787 (2010). 147 Tremblay, E., Martineau, E. & Robitaille, R. Opposite Synaptic Alterations at the Neuromuscular Junction in an ALS Mouse Model: When Motor Units Matter. J Neurosci 37, 8901-8918, doi:10.1523/JNEUROSCI.3090-16.2017 (2017). 148 de Jong, S. et al. Endogenous female reproductive hormones and the risk of amyotrophic lateral sclerosis. Journal of neurology 260, 507-512, doi:10.1007/s00415-012-6665-5 (2013). 149 Nakamizo, T. et al. Protection of cultured spinal motor neurons by estradiol. Neuroreport 11, 3493-3497 (2000). 150 Orsini, M. et al. Amyotrophic Lateral Sclerosis: New Perpectives and Update. Neurol Int 7, 5885, doi:10.4081/ni.2015.5885 (2015). 151 Neumann, M. et al. TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. Journal of neuropathology and experimental neurology 66, 177-183, doi:10.1097/01.jnen.0000248554.45456.58 (2007). 152 Hirano, A. Neuropathology of ALS: an overview. Neurology 47, S63-66 (1996). 153 Philips, T. & Rothstein, J. D. Glial cells in amyotrophic lateral sclerosis. Exp Neurol 262 Pt B, 111-120, doi:10.1016/j.expneurol.2014.05.015 (2014). 154 Wang, C. & Wang, X. The interplay between autophagy and the ubiquitin-proteasome system in cardiac proteotoxicity. Biochim Biophys Acta 1852, 188-194, doi:10.1016/j.bbadis.2014.07.028 (2015). 155 Marquez, R. T. & Xu, L. Bcl-2:Beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch. Am J Cancer Res 2, 214-221 (2012). 156 Pfisterer, U. & Khodosevich, K. Neuronal survival in the brain: neuron type-specific mechanisms. Cell Death Dis 8, e2643, doi:10.1038/cddis.2017.64 (2017). 157 Sephton, C. F. et al. Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J Biol Chem 286, 1204-1215, doi:10.1074/jbc.M110.190884 (2011). 158 Tsuiji, H. et al. TDP-43 accelerates age-dependent degeneration of interneurons. Sci Rep 7, 14972, doi:10.1038/s41598-017-14966-w (2017). 159 Prudencio, M. et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nature neuroscience 18, 1175-1182, doi:10.1038/nn.4065 (2015). 160 Lee, S. & Huang, E. J. Modeling ALS and FTD with iPSC-derived neurons. Brain research 1656, 88-97, doi:10.1016/j.brainres.2015.10.003 (2017). 161 Lautenschlager, J. et al. Overexpression of human mutated G93A SOD1 changes dynamics of the ER mitochondria calcium cycle specifically in mouse embryonic motor neurons. Exp Neurol 247, 91-100, doi:10.1016/j.expneurol.2013.03.027 (2013). 162 Doutheil, J., Gissel, C., Oschlies, U., Hossmann, K. A. & Paschen, W. Relation of neuronal endoplasmic reticulum calcium homeostasis to ribosomal aggregation and protein synthesis: implications for stress-induced suppression of protein synthesis. Brain research 775, 43-51 (1997). 163 Wang, W. et al. The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and functi | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/21756 | - |
dc.description.abstract | 肌肉萎縮性側索硬化症(俗稱漸凍症)或稱盧-葛雷克氏症,是種漸進且致命的成年型退化性疾病,為延髓區域和脊髓中的上下運動神經元退化,最終導致病患無法自主隨意肌而癱瘓。超過百分之九十五漸凍症患者的脊髓運動神經元細胞質中,皆發現TDP-43的代謝異常(ALS-TDP)。雖然目前已有50多種與ALS相關的TDP-43氨基酸突變點被鑑定出來,但是這些突變如何實際影響漸凍症的發病機制尚不清楚。本文中,我們建立兩種同源基因嵌入小鼠品系,分別帶有與遺傳性漸凍症有關之TDP-43(A315T),以及突發性漸凍症突變,TDP-43(N390D)。值得注意的是,只有N390D/+小鼠,在運動行為、細胞和分子層次上,全面的發展出年齡依賴性類漸凍症發病模式。我們利用嵌入小鼠與其胚胎幹細胞誘導分化之脊髓運動神經元,來探討分子層次上TDP-43的不同突變點引起神經退化能力的差異性。結果顯示,N390D/+小鼠而非A315T/+小鼠,在發病前其小鼠脊隨中的TDP-43蛋白質隨著年紀增長開始累積; 發病後,進一步偵測到TDP-43與TDP-43之小片段(TDP-35與TDP-25)蛋白質代謝異常與自噬系統功能缺損。不同的ALS相關TDP-43突變具有關鍵的ALS引起的能力和致病途徑,可能由其遺傳背景和環境因素改變。 機制上,我們發現在ALS-TDP致病過程的早期階段,TDP-43(N390D / +)藉由調控Bcl-2 mRNA選擇性剪輯,提高Bcl-2的蛋白質表現,導致自噬功能障礙和細胞質鈣離子水平升高,而使運動神經元(N390D/+)比 (+/+)或(A315T/+) 來得脆弱。當環境中存在有壓力時,引起運動神經元(A315T/+)中TDP-43蛋白表現量的上升和運動神經元退化與死亡。證實TDP-43突變的運動神經元,對於環境壓力存在之耐受性較為低落。總結來說,TDP-43(N390D/+)與(A315T/+)嵌入小鼠模式可以提供期待已久的機會,分別暸解ALS-TDP致病的早期機制與環境因素如何調節ALS-TDP致病過程。 | zh_TW |
dc.description.abstract | Amyotrophic lateral sclerosis (ALS) is a fatal, adult-onset degenerative disorder of motor neurons. The diseased spinal cord motor neurons of more than 95% of amyotrophic lateral sclerosis (ALS) patients are characterized by the mis-metabolism of the RNA/DNA-binding protein TDP-43 (ALS-TDP), in particular the presence of cytosolic aggregates of the protein. Most available mouse models for the basic or translational studies of ALS-TDP are based on transgenic overexpression of the TDP-43 protein. Here, we report the generation and characterization of mouse lines bearing homologous knock-in of familial ALS-associated mutation A315T and sporadic ALS-associated mutation N390D, respectively. Remarkably, the heterozygous TDP-43 (N390D/+) mice but not those heterozygous for the TDP-43 (A315T/+) mice develop a full spectrum of ALS-TDP-like pathologies at the molecular, cellular and behavioral levels. Comparative analysis of the mutant mice and spinal cord motor neuron (MN) derived from their embryonic stem cell demonstrates that different ALS-associated TDP-43 mutations possess critical ALS-causing capabilities and pathogenic pathways, likely modified by their genetic background and the environmental factors. Mechanistically, we identify aberrant RNA splicing of spinal cord Bcl-2 pre-mRNA and consequent increase of a negative regulator of autophagy, Bcl-2, which correlate with and are caused by a progressive increase of TDP-43 in spinal cord MN - one of the early events associated with ALS-TDP pathogenesis. The environmental stresses caused increase of TDP-43 in the (A315T/+) MN and the MN degeneration and death implying the MN carrying mutant TDP-43 is much more fragile than the (+/+) MN. Briefly, the TDP-43 (N390D/+) knock-in mouse model provides a long-awaited opportunity for basic as well as translational studies of ALS-TDP. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T03:45:26Z (GMT). No. of bitstreams: 1 ntu-108-D01448002-1.pdf: 12968994 bytes, checksum: 2dd4e789bfc0f8c1c5b7147529ee075b (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | Content
口試委員會審定書 page 1 Main Text 致謝(ACKNOWLEDGMENTS) 2 中文摘要 5 ABSTRACT 6 I. INTRODUCTION 7 I.1 AMYOTROPHIC LATERAL SCLEROSIS 7 I.2 TAR DNA BINDING PROTEIN WITH 43 KDA (TDP-43) 11 I.3 CURRENTLY AVAILABLE ALS-TDP RODENT MODELS 15 I.4 RATIONALE 16 I.5 OBJECT 17 II. MATERIALS AND METHODS 19 III. RESULTS 30 III.1 GENERATION OF KNOCK-IN MICE WITH A315T AND N390D 30 III.2 AGE-DEPENDENT ALS-LIKE PHENOTYPES OF N390D/+, BUT NOT A315T, MICE 31 III.3 MOLECULAR AND CELLULAR PATHOLOGY OF N390D/+ MALE MICE 33 III.4 ALTERNATION OF PROTEASOME ACTIVITY AND AUTOPHAGY 36 III.5 INCREASE OF SPINAL CORD BCL-2 PROTEIN AS A CONSEQUENCE OF MIS-REGULATION OF BCL-2 PRE-MRNA SPLICING IN N390D/+ MALE MICE 37 III.6 CELL-AUTONOMOUS EFFECT OF ESC-DERIVED MOTOR NEURON (N390D/+) 38 III.7 CHANGES OF CALCIUM ION HOMEOSTASIS IN CULTURED (N390D/+) MN 40 III.8 PROMOTION OF SPINAL MN DEGENERATION VIA ENVIRONMENTAL INSULTS 41 IV. CONCLUSION AND DISCUSSION 42 V. FIGURES AND FIGURE LEGENDS 49 FIGURE 1. GENERATION OF KNOCK-IN MICE WITH ALS-ASSOCIATED MUTATIONS, A315T AND N390D. 50 FIGURE 2. AGE-DEPENDENT ALS-LIKE PHENOTYPES OF HETEROZYGOUS N390D/+ MICE. 54 FIGURE 3. COGNITION ANALYSIS OF N390D/+ MALE MICE. 59 FIGURE 4. PATHO-SIGNATURE ANALYSIS OF TDP-43 IN SPINAL CORD OF HETEROZYGOUS N390D/+ KNOCK-IN MICE. 69 FIGURE 5. EFFECTS OF TDP-43 (N390D) MUTATION ON PROTEASOME ACTIVITY, AUTOPHAGY, AND BCL-2 EXPRESSION. 75 FIGURE 6. COMPARATIVE ANALYSIS OF PATHO-SIGNATURES AND NEURODEGENERATION OF CULTURED SPINAL CORD MN DERIVED FROM +/+ AND MUTANT ESC. 80 FIGURE 7. MIS-REGULATION OF BCL-2 EXPRESSION AND CALCIUM ION HOMEOSTASIS IN CULTURED (N390D/+) MN. 83 FIGURE 8. ACCELERATED NEURODEGENERATION OF CULTURED MUTANT SPINAL MN BY ENVIRONMENTAL INSULTS. 85 FIGURE 9. AGE-DEPENDENT ALS-TDP-LIKE PATHOGENESIS OF TDP-43 (N390D/+) MICE. 87 FIGURE 10. A MODEL OF THE ALS-TDP-LIKE PATHOGENESIS OF TDP-43 (N390D/+) MICE. 88 VI. TABLES AND SUPPLEMENTARY RESULT 89 TABLE 1 89 TABLE 2 89 TABLE 3 90 VII. REFERENCES AND NOTE 94 | |
dc.language.iso | en | |
dc.title | ALS相關TDP-43突變對同源嵌入小鼠ALS發病機制的影響差異 | zh_TW |
dc.title | Diacritical Effects of ALS-Associated TDP-43 Mutations on ALS Pathogenesis in Homologous Knock-in Mice | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 潘俊良,簡正鼎,鄭珮琳,陳韻如 | |
dc.subject.keyword | TDP-43,肌肉萎縮性側索硬化症,漸凍症,運動神經元退化性疾病,Bcl-2,自噬功能, | zh_TW |
dc.subject.keyword | TDP-43,ALS,MND,Bcl-2,autophagy, | en |
dc.relation.page | 104 | |
dc.identifier.doi | 10.6342/NTU201900592 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2019-02-14 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
顯示於系所單位: | 分子醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 12.67 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。